Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oramed Pharmaceuticals has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a combination therapy of ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901, for oral treatment of diabetes.
Subscribe to our email newsletter
According to the company, the combined use of these two drugs has recently been evaluated in animals and showed improved blood glucose regulation when compared to the administration of each drug separately.
Both drugs are currently being independently evaluated in human clinical trials.
The formulations have been designed to allow for oral delivery of drugs currently only available in injectable forms.